Related Experiment Videos
Viral vectors for cancer immunotherapy
Richard Harrop1, Miles W Carroll
1Oxford BioMedica Ltd., Oxford Science Park, Oxford, OX4 4GA, United Kingdom.
Frontiers in Bioscience : a Journal and Virtual Library
|September 9, 2005
Summary
Cancer immunotherapy is advancing with viral vectors delivering tumor antigens. These viral systems show promise for potent, targeted antitumor responses, moving from pre-clinical to clinical development.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Immunotherapy has gained traction for cancer treatment, spurred by successes in antibody and cytokine therapies.
- Identifying tumor-associated antigens (TAAs) allows for targeted immunotherapies, reducing autoimmune concerns.
- Effective cancer vaccines require robust antigen delivery systems.
Purpose of the Study:
- To review the progress and clinical development of viral vectors for cancer immunotherapy.
- To highlight the importance of antigen delivery systems in cancer vaccine development.
Main Methods:
- Review of pre-clinical and clinical studies involving oncolytic viruses and recombinant viral vectors.
- Focus on viral vectors engineered to deliver TAAs or therapeutic genes.
Main Results:
- Viral vectors can induce potent and targeted antitumor immune responses.
- Numerous recombinant viral vectors have advanced from pre-clinical research to clinical trials.
- These viral systems are crucial for developing novel cancer immunotherapies.
Conclusions:
- Viral vector-based cancer immunotherapies represent a significant area of ongoing research and development.
- The use of viruses as delivery systems for TAAs is a key strategy in modern cancer vaccine design.